Treg cell therapy for COVID-19 and acute respiratory distress
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new cell therapy using Treg cells from thymic tissue to calm an overactive immune response in severe COVID-19 and ARDS. It aims to improve breathing and reduce inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 65 years old
- Have severe lung injury from COVID-19 or other causes with bilateral lung infiltrates and low oxygen levels
- Have high inflammation markers like IL-6, ferritin, or C-reactive protein
- Not be pregnant or breastfeeding
- Have a body mass index (BMI) of 35 or less
- Not have serious bleeding issues (low platelets) or low white blood cell count
- Be free of active hepatitis B, C, or HIV infections
- Not have other major health problems like autoimmune disease, cancer, or prior organ transplant
- Not have used certain immune-suppressing drugs or other cell therapies recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a cell treatment (Treg cells made from a child’s thymus tissue) to help prevent the body from rejecting a new heart. It may help reduce rejection risk, but it is experimental and involves added risks and follow-up.
This trial tests a new treatment using special white blood cells (called Treg cells) to help control graft-versus-host disease (GVHD), a common complication after a stem cell transplant. The goal is to reduce GVHD symptoms without the serious side effects of high-dose steroids.
This trial tests a new type of cell therapy called regulatory T cells (Tregs) for people with neurodegenerative diseases like ALS. The goal is to see if these cells can slow down the disease.
This trial tests whether an injection of stem cells from umbilical cords can help people with severe ARDS (a type of lung failure) recover faster. It is for those who have not improved after standard treatment and whose ARDS is caused by an infection (not COVID-19).
This study tests an investigational stem cell treatment called MesenCure for people with acute respiratory distress syndrome (ARDS), a serious lung condition that often occurs with COVID-19. The treatment may help reduce lung inflammation and improve breathing.
This early-phase study tests immune cells from a matched family donor (made to target the COVID-19 virus) to see if they can help people with mild-to-moderate COVID-19 who are hospitalized and at higher risk for getting sicker. It aims to check safety first and also look for signs of benefit.
Hear when a new Systemic Inflammatory Response Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.